Abstract

Progress in sample preparation for scRNA-seq is reported based on RevGel-seq, a reversible-hydrogel technology optimized for samples of fresh cells. Complexes of one cell paired with one barcoded bead are stabilized by a chemical linker and dispersed in a hydrogel in the liquid state. Upon gelation on ice the complexes are immobilized and physically separated without requiring nanowells or droplets. Cell lysis is triggered by detergent diffusion, and RNA molecules are captured on the adjacent barcoded beads for further processing with reverse transcription and preparation for cDNA sequencing. As a proof of concept, analysis of PBMC using RevGel-seq achieves results similar to microfluidic-based technologies when using the same original sample and the same data analysis software. In addition, a clinically relevant application of RevGel-seq is presented for pancreatic islet cells. Furthermore, characterizations carried out on cardiomyocytes demonstrate that the hydrogel technology readily accommodates very large cells. Standard analyses are in the 10,000-input cell range with the current gelation device, in order to satisfy common requirements for single-cell research. A convenient stopping point after two hours has been established by freezing at the cell lysis step, with full preservation of gene expression profiles. Overall, our results show that RevGel-seq represents an accessible and efficient instrument-free alternative, enabling flexibility in terms of experimental design and timing of sample processing, while providing broad coverage of cell types.

Details

Title
RevGel-seq: instrument-free single-cell RNA sequencing using a reversible hydrogel for cell-specific barcoding
Author
Komatsu, Jun 1 ; Cico, Alba 1 ; Poncin, Raya 1 ; Le Bohec, Maël 1 ; Morf, Jörg 2 ; Lipin, Stanislav 1 ; Graindorge, Antoine 1 ; Eckert, Hélène 1 ; Saffarian, Azadeh 1 ; Cathaly, Léa 1 ; Guérin, Frédéric 1 ; Majello, Sara 1 ; Ulveling, Damien 1 ; Vayaboury, Anaïs 1 ; Fernandez, Nicolas 1 ; Dimitrova, Dilyana 1 ; Bussell, Xavier 1 ; Fourne, Yannick 1 ; Chaumat, Pierre 1 ; André, Barbara 1 ; Baldivia, Elodie 1 ; Godet, Ulysse 1 ; Guinin, Mathieu 1 ; Moretto, Vivien 1 ; Ismail, Joy 1 ; Caille, Olivier 1 ; Roblot, Natacha 3 ; Beaupère, Carine 3 ; Liboz, Alexandrine 3 ; Guillemain, Ghislaine 3 ; Blondeau, Bertrand 3 ; Walrafen, Pierre 4 ; Edelstein, Stuart 4 

 Scipio Bioscience, Paris, France 
 Scipio Bioscience, Paris, France; Skyhawk Therapeutics, Basel, Switzerland 
 Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929) 
 Scipio Bioscience, Paris, France (GRID:grid.465261.2) 
Pages
4866
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2790223024
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.